An influence of therapy agaist renal anemia and secondary hyperparathyroidism on iron dysregulation in patients with chronic kidney disease

An influence of therapy agaist renal anemia and secondary hyperparathyroidism on iron dysregulation in patients with chronic kidney disease - REIST study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011613

Enrollment

100

Registered

2013-09-02

Start date

2013-09-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Treatment with long-acting ESA against renal anemia Conventional treatment with any ESA against renal anemia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic kidney disease patients with serum ferritin >250 ng/ml

Exclusion criteria

Exclusion criteria: Malignant disease, hematological disease, severe infection, bleeding

Design outcomes

Primary

Measure	Time frame
A decrease in serum level of ferritin	—

Secondary

Measure	Time frame
Anemia/iron: ESA responsiveness, serum iron, TIBC, Tsat, hepcidin, frataxin, sTfR, etc. Oxidative stress/inflammation: 8OHdG, AOPP, MDA, GSH, PNT, high-sensitivity CRP,TNF, IL-6, etc. MBD: iPTH, wPTH, BAP, TRAP5b, vitaminD,TropT, PTX, FGF23, etc	—

Countries

Japan

Contacts

Public ContactYukiko Hasuike

Hyogo College of Medicine Division fo Kidney and Dialysis, Department of Internal Medicine

cherry39@hyo-med.ac.jp0798456521

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026